Roche has announced results from CLEOPATRA, the first randomised phase III study of the investigational HER2-targeted medicine pertuzumab.
The study compared the combination of pertuzumab, trastuzumab and docetaxel chemotherapy to trastuzumab and docetaxel alone in people with previously untreated HER2-positive metastatic breast cancer (mBC).
People who received pertuzumab in combination with trastuzumab and chemotherapy experienced a 38 per cent reduction in the risk of their disease worsening or death (progression-free survival, or PFS), (HR=0.62; p-value=<0.0001).
The median PFS improved by 6.1 months from 12.4 months for trastuzumab and chemotherapy to 18.5 months for pertuzumab, trastuzumab and chemotherapy. Overall survival (OS) data are currently immature, with a trend in favour of the pertuzumab combination, Roche stated.
